GSK plc announced on February 6, 2024, that its application for Shingrix, aimed at preventing shingles in at-risk adults aged 18+, has been accepted for review by the China National Medical Products Administration. This could expand protection against shingles for a significant population, given the estimated 6 million cases in China annually.